Stem Cells for Acute Kidney Injury
(AKI Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are using medications that suppress the immune system, you may not be eligible to participate.
What data supports the effectiveness of the treatment Allogeneic HB-adMSCs for acute kidney injury?
Is the use of adipose-derived mesenchymal stem cells safe for treating kidney injuries?
How is the treatment Allogeneic HB-adMSCs different from other treatments for acute kidney injury?
Allogeneic HB-adMSCs (adipose-derived mesenchymal stem cells) are unique because they use stem cells from fat tissue to help repair kidney damage, potentially offering a regenerative approach that other treatments do not provide. This treatment focuses on reducing kidney injury and improving function by modulating the kidney's response to damage, which is different from standard treatments that may only manage symptoms.12358
What is the purpose of this trial?
This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).
Research Team
Charles S Cox, Jr., MD
Principal Investigator
The University of Texas Health Science Center, Houston
Eligibility Criteria
This trial is for individuals with trauma-induced Acute Kidney Injury (AKI). Specific eligibility criteria are not provided, but typically participants must meet certain health conditions and cannot have factors that would exclude them from safely participating.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 3 infusions of allogeneic adipose-derived MSCs or placebo daily for 3 days
Follow-up
Participants are monitored for safety and effectiveness after treatment, including monitoring for infusion-related adverse events and progression of AKI
Long-term follow-up
Participants are monitored for long-term outcomes such as mortality, recurrent AKI, and post-injury organ dysfunction
Treatment Details
Interventions
- Allogeneic HB-adMSCs
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hope Biosciences
Lead Sponsor
University of California, San Francisco
Collaborator
The University of Texas Health Science Center, Houston
Collaborator
University of Alabama at Birmingham
Collaborator